Unadjusted response and remission rates and adjusted likelihoods of achieving response/remission over time stratified by anti-TNF switch status
| 6 Months | 12 Months | |||||
|---|---|---|---|---|---|---|
| Biologically naive | First-time switcher | Second-time switcher | Biologically naive | First-time switcher | Second-time switcher | |
| mACR response | ||||||
| No of patients | 687 | 319 | 73 | 550 | 251 | 67 |
| mACR 20 | ||||||
| Responders | 30.5% | 19.9% | 17.3% | 28.5% | 14.7% | 18.7% |
| Adjusted OR (95% CI)† | 1 | 0.54 (0.38 to 0.76)* | 0.42 (0.23 to 0.78)* | 1 | 0.44 (0.30 to 0.66)* | 0.50 (0.25 to 0.99)* |
| mACR50 | ||||||
| Responders | 20.2% | 9.4% | 9.9% | 18.9% | 8.8% | 9.3% |
| Adjusted OR (95% CI)† | 1 | 0.42 (0.27 to 0.65)* | 0.42 (0.20 to 0.86)* | 1 | 0.49 (0.30 to 0.78)* | 0.41 (0.17 to 0.99)* |
| mACR70 | ||||||
| Responders | 10.3% | 2.6% | 4.9% | 11.4% | 3.7% | 4.0% |
| Adjusted OR (95% CI)† | 1 | 0.28 (0.14 to 0.55)* | 0.50 (0.19 to 1.32) | 1 | 0.39 (0.19 to 0.80)* | 0.23 (0.05 to 1.05) |
| CDAI remission | ||||||
| No of patients | 745 | 334 | 75 | 590 | 263 | 67 |
| Responders | 15.4% | 7.3% | 1.2% | 16.2% | 8.8% | 5.3% |
| Adjusted OR (95% CI)‡ | 1 | 0.57 (0.36 to 0.90)* | 0.09 (0.01 to 0.71)* | 1 | 0.63 (0.38 to 1.04) | 0.32 (0.10 to 1.03) |
| DAS28–ESR remission | ||||||
| No of patients | 326 | 136 | 41 | 218 | 85 | 27 |
| Responders | 25.1% | 7.6% | 7.5% | 29.3% | 10.3% | 9.4% |
| Unadjusted OR (95% CI)ठ| 1 | 0.21 (0.08 to 0.56)* | 0.29 (0.07 to 1.22)* | 1 | 0.21 (0.07 to 0.65)* | 0.31 (0.06 to 1.59) |
Data presented are the percentage of patients or adjusted OR (95% CI).
↵* p<0.05.
↵† Derived via multivariate logistical regression analyses adjusted for age, disease duration, swollen joint count, tender joint count, modified HAQ disability index, patient global assessment, self-reported disability, methotrexate use and year since anti-TNF initiation.
‡ Derived via multivariate logistical regression analyses adjusted for age, disease duration, baseline disease activity, self-reported disability, methotrexate use and years since anti-TNF initiation.
§ Inadequate sample size for examination of adjusted likelihoods.
CDAI, clinical disease activity index; DAS28, disease activity score employing 28-joint count; ESR, erythrocyte sedimentation rate; mACR, modified American College of Rheumatology; TNF, tumour necrosis factor.